RecruitingPHASE1, PHASE2NCT05006716
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Studying B-cell chronic lymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BeOne Medicines
- Principal Investigator
- Study DirectorBeOne Medicines
- Intervention
- BGB-16673(drug)
- Enrollment
- 614 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2029
Study locations (30)
- University of Alabama At Birmingham Hospital, Birmingham, Alabama, United States
- Mayo Clinic Phoenix, Phoenix, Arizona, United States
- Honor Health Research Institute, Scottsdale, Arizona, United States
- University of Arizona Cancer Center, Tucson, Arizona, United States
- University of California San Diego (Ucsd) Moores Cancer Center, La Jolla, California, United States
- Stanford Medicine, Palo Alto, California, United States
- UCLA Santa Monica Cancer Care, Santa Monica, California, United States
- Uchealth North, Fort Collins, Colorado, United States
- Mayo Clinic Jacksonville, Jacksonville, Florida, United States
- Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
- Tampa General Hospital Cancer Institute, Tampa, Florida, United States
- Augusta University, Augusta, Georgia, United States
- Southeastern Regional Medical Center, Newnan, Georgia, United States
- Midwestern Regional Medical Center, Zion, Illinois, United States
- University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05006716 on ClinicalTrials.govOther trials for B-cell chronic lymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center
- RECRUITINGEARLY PHASE1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE4NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and Company
- RECRUITINGPHASE1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center
- RECRUITINGPHASE2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPHASE2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer
- RECRUITINGPHASE2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn